CDK4 and cancer: The results of both phase I/II in terms of clinical safety and efficacy prompted the initiation of a phase III trial (VERITAC-2) where a 200 mg ARV-471 dosage was selected to be compared with Fulvestrant in patients with the same cancer whose cancer progressed even after prior endocrine based treatment in combination with CDK4/6 inhibitor therapy.